Schedule 13G ownership disclosure
4D Molecular Therapeutics Inc
Security class unavailable · CUSIP: 35104E100
Event date: Unavailable
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 4,965,019
- Percent of class
- 10.7000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002012383-24-004549
- Form type
- SC 13G
- Filer
- 4D Molecular Therapeutics, Inc.
- CIK
- CIK 1650648
- Filed
- Dec 06, 2024
- Reporting period
- —
- Description
- Schedule 13G beneficial ownership